跳至主要内容
临床试验/EUCTR2017-003436-36-GB
EUCTR2017-003436-36-GB进行中(未招募)1 期

Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity

ovo Nordisk A/S0 个研究点目标入组 1,950 人开始时间: 2018年2月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
1,950

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1. Male or female, age = 18 years at the time of signing informed consent
  • 2. Body mass index (BMI) = 30 kg/sqm or = 27 kg/sqm with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
  • 3. History of at least one self-reported unsuccessful dietary effort to lose body weight
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 1560
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 390

排除标准

  • 1. HbA1C = 48 mmol/mol (6.5%) as measured by the central laboratory at screening
  • 2. A self-reported change in body weight > 5 kg (11 lbs) within 90 days before screening irrespective of medical records

研究者

相似试验

Research study investigating how well semaglutide... | 临床试验